Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q3 2013 · 10-Q
Revenue$505.10M$505.10M+1.3% vs Q3 2012 Net Income-$7.10M-$7.10MN/M vs Q3 2012 EPS Diluted-$0.25-$0.25N/M vs Q3 2012 Gross Profit$284,200,000+3.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$54,832,000−23.1% Free Cash Flowderived$34,492,000−0.5% Margins · derivedGross margin56.3%+1.4 pt vs Q3 2012
Operating margin5.8%−7.4 pt vs Q3 2012
Net margin-1.4%−10.0 pt vs Q3 2012
ended Sep 30, 2013 · filed Nov 12, 2013 · 43 d after period end